Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Lin, Chien Hung ^a,b   Shen, Yao An ^a   Hung, Peir Haur ^c   Yu, Yuan Bin ^d   Chen, Yann Jang ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cancer stem cells; Epigallocathechin gallate; Epithelial mesenchymal transition; Nasopharyngeal carcinoma; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; EPIGALLOCATECHIN GALLATE; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RECURRENCE; CARCINOGENICITY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL RENEWAL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; NASOPHARYNX CANCER; PHENOTYPE; PROTEIN EXPRESSION; TEA;

EID: 84867895444     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-201     Document Type: Article

References (45)

1. Cheung F, Chan O, Ng WT, Chan L, Lee A, Pang SW. The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncol 2012, 48(5):429-433. 10.1016/j.oraloncology.2011.11.017, 22177891.
2. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5(5):423-428. 10.1016/S1535-6108(04)00119-9, 15144950.
3. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005, 62(3):672-679. 10.1016/j.ijrobp.2004.11.002, 15936544.
4. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006, 355(12):1253-1261. 10.1056/NEJMra061808, 16990388.
5. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284. 10.1146/annurev.med.58.062105.204854, 17002552.
6. Frame FM, Maitland NJ. Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol 2011, 720:105-118. 10.1007/978-1-4614-0254-1_9, 21901622.
7. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007, 67(8):3716-3724. 10.1158/0008-5472.CAN-06-4343, 17440084.
8. Su J, Xu XH, Huang Q, Lu MQ, Li DJ, Xue F, Yi F, Ren JH, Wu YP. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res 2011, 42(1):15-21. 10.1016/j.arcmed.2011.01.007, 21376257.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
10. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5(8):e12445. 10.1371/journal.pone.0012445, 2929211, 20805998.
11. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009, 14(1):29-43. 10.1007/s10911-009-9110-3, 19242781.
12. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273. 10.1038/nrc2620, 19262571.
13. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9(5):391-403. 10.1016/j.ccr.2006.03.030, 16697959.
14. Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 2004, 23(14):2507-2522. 10.1038/sj.onc.1207353, 14676829.
15. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000, 376(2):338-346. 10.1006/abbi.2000.1742, 10775421.
16. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 2007, 12:4881-4899. 10.2741/2435, 17569617.
17. Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007, 12:5039-5051. 10.2741/2446, 17569628.
18. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003, 133(7 Suppl):2417S-2424S.
19. Wang X, Hao MW, Dong K, Lin F, Ren JH, Zhang HZ. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res 2009, 32(9):1263-1269. 10.1007/s12272-009-1912-8, 19784583.
20. Chan MM, Soprano KJ, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 2006, 207(2):389-396. 10.1002/jcp.20569, 16402374.
21. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007, 245(1-2):232-241.
22. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 2010, 293(1):65-72. 10.1016/j.canlet.2009.12.018, 2862867, 20089354.
23. Burnett J, Newman B, Sun D. Targeting cancer stem cells with natural products. Curr Drug Targets 2012, 13(8):1054-1064. 10.2174/138945012802009062, 22594473.
24. Hu FW, Tsai LL, Yu CH, Chen PN, Chou MY, Yu CC. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res 2012, 56(8):1247-1258. 10.1002/mnfr.201200150, 22692956.
25. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
26. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011, 128(2):79-85. 10.1016/j.anorl.2010.10.003, 21177151.
27. Lin J-C, Liao S-K, Lee E-H, Hung M-S, Sayion Y, Chen H-C, Kang C-C, Huang L-S, Cherng J-M. Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome. J Biomed Sci 2009, 16(1):105. 10.1186/1423-0127-16-105, 2799403, 19930697.
28. Hueng DY, Sytwu HK, Huang SM, Chang C, Ma HI. Isolation and characterization of tumor stem-like cells from human meningiomas. J Neurooncol 2011, 104(1):45-53. 10.1007/s11060-010-0469-1, 21116836.
29. Zhong Y, Guan K, Guo S, Zhou C, Wang D, Ma W, Zhang Y, Li C, Zhang S. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett 2010, 299(2):150-160. 10.1016/j.canlet.2010.08.013, 20846785.
30. Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature 2004, 430(7003):973-974. 10.1038/430973a, 15329701.
31. Tran PL, Kim SA, Choi HS, Yoon JH, Ahn SG. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 2010, 10:276. 10.1186/1471-2407-10-276, 2927993, 20537126.
32. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem 1999, 75(1):1-12. 10.1002/(SICI)1097-4644(19991001)75:1<1::AID-JCB1>3.0.CO;2-N, 10462699.
33. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000, 164(1):82-90. 10.1006/taap.1999.8885, 10739747.
34. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003, 410(1):177-185. 10.1016/S0003-9861(02)00668-9, 12559991.
35. Chen SF, Chang YC, Nieh S, Liu CL, Yang CY, Lin YS. Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS One 2012, 7(2):e31864. 10.1371/journal.pone.0031864, 3281010, 22359637.
36. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011, 30(18):2161-2172. 10.1038/onc.2010.591, 3088782, 21242971.
37. Kim RJ, Nam JS. OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 2011, 27(2):147-152. 10.5625/lar.2011.27.2.147, 3145994, 21826175.
38. Tang S-N, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signaling 2010, 5(1):14.
39. Chen D, Pamu S, Cui Q, Chan TH, Dou QP. Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem 2012, 20(9):3031-3037. 10.1016/j.bmc.2012.03.002, 22459208.
40. Luo W, Fang W, Li S, Yao K. Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Canc 2012, 131(8):1863-1873.
41. Yip WK, Seow HF. Activation of phosphatidylinositol 3-kinase/Akt signaling by EGF downregulates membranous E-cadherin and beta-catenin and enhances invasion in nasopharyngeal carcinoma cells. Cancer Lett 2012, 318(2):162-172. 10.1016/j.canlet.2011.12.018, 22182447.
42. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008, 52(Suppl 1):S139-151.
43. Osanai K, Landis-Piwowar KR, Dou QP, Chan TH. A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer. Bioorg Med Chem 2007, 15(15):5076-5082. 10.1016/j.bmc.2007.05.041, 2963865, 17544279.
44. Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 1998, 129(2):173-179. 10.1016/S0304-3835(98)00108-6, 9719459.
45. Yamamoto T, Hsu S, Lewis J, Wataha J, Dickinson D, Singh B, Bollag WB, Lockwood P, Ueta E, Osaki T, et al. Green tea polyphenol causes differential oxidative environments in tumor versus normal epithelial cells. J Pharmacol Exp Ther 2003, 307(1):230-236. 10.1124/jpet.103.054676, 12954803.